Niki BioSolutions, Inc. Stock-Based Compensation
Niki BioSolutions, Inc. (NIKI) reported Stock-Based Compensation of $1.27 million for the 12-month period ending 2023-12-31, per its S-4/A filed 2026-05-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-05-11
| Period end | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|
| 2023-12-31 | $1.27M S-4/A · filed 2026-05-11 | |
| 2023-06-30 | $711.92K 6-K · filed 2024-12-20 | |
| 2022-12-31 | $1.65M 6-K · filed 2025-10-08 | |
| 2022-06-30 | $683.33K 6-K · filed 2023-12-22 | |
| 2021-12-31 | $1.68M 20-F · filed 2024-04-30 | |
| 2021-06-30 | $712.92K 6-K · filed 2022-09-30 | |
| 2020-12-31 | $1.48M 20-F · filed 2023-04-28 | |
| 2020-06-30 | $584.09K 6-K · filed 2020-09-02 | |
| 2019-12-31 | $1.61M 20-F/A · filed 2023-01-17 | |
| 2019-06-30 | $593.81K 6-K · filed 2020-09-02 |